Patents
Literature
10 results about "Adrenergic antagonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An adrenergic antagonist is a drug that inhibits the function of adrenergic receptors. There are five adrenergic receptors, which are divided into two groups. The first group of receptors are the beta (β) adrenergic receptors. There are β₁, β₂, and β₃ receptors. The second group contains the alpha (α) adrenoreceptors. There are only α₁ and α₂ receptors. Adrenergic receptors are located near the heart, kidneys, lungs, and gastrointestinal tract. There are also α-adreno receptors that are located on vascular smooth muscle.
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.
Owner:OCUPHIRE PHARM INC
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.
Owner:OCUPHIRE PHARM INC
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.
Owner:OCUPHIRE PHARM INC
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.
Owner:OCUPHIRE PHARM INC
Adrenergic antagonists for use in a method for treating cerebral edema or a brain injury
PCT designated stage expiredWO2025034510A1Organic active ingredientsNervous disorderAdrenergic antagonistDisease
Owner:UNIVERSITY OF ROCHESTER
Exercise effect-mimicking agent
The present disclosure aims to provide an exercise effect-mimicking agent capable of producing effects similar to those of exercise without actually exercising. An exercise effect-mimicking agent containing at least one compound selected from the group consisting of (A) an α-adrenergic antagonist, (B) a flavonoid, (C) a dopamine D2 receptor antagonist, and (D) an NF-κB signaling pathway inhibitor.
Owner:KOBE UNIV
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.
Owner:OPUS GENETICS INC
Methods and compositions for the treatment of drug overdose
PendingUS20240415829A1Organic active ingredientsAntinoxious agentsBenzodiazepineAdrenergic antagonist
Described herein are lifesaving compositions and methods including the administration of alpha-2 (α2) adrenergic antagonists as a drug class for use in the reversal of substance overdose that can be contributed to by xylazine and xylazine congeners, alcohol, fentanyl / opioids, and benzodiazepines in humans. In some instances, the substance overdoses can appear to be opioid induced but are not responsive to administration of therapeutic agents (e.g., Naloxone administration). The antagonists can be safely and quickly produced using yohimbine, and the compositions and methods are operative to address the United States' national crisis of human overdoses caused by combining various illicit (street) drugs with xylazine.
Owner:BROWN UNIVERSITY
Vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing
ActiveUS12280057B2Ester active ingredientsAluminium/calcium/magnesium active ingredientsAdrenergic antagonistBlood flow
The present disclosure relates to compositions and systems for improving tissue perfusion such that blood flow is increased, improving tissue healing time and reducing or eliminating tissue necrosis. In a preferred embodiment, the compositions comprise a phosphodiesterase inhibitor, a calcium channel blocker, a nitric oxide producer, and an α-adrenergic antagonist. Methods of making the compositions and using the compositions are also disclosed.
Owner:SOUTH DAKOTA BOARD OF REGENTS
Methods and compositions for treatment of mydriasis
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.
Owner:OPUS GENETICS INC